SLC5A2 and diabetes mellitus: Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT-2) inhibitors are both agents that have been associated with reductions in cardiovascular mortality and they may eventually play a role in the management of cardiovascular disease and diabetes after HSCT.53